Patient-friendly summary
If you read nothing else
Bottom line
No single drug reliably controls fibromyalgia; first-line medications offer modest, often short-lived benefit and should supplement, not replace, non-drug self-management, while strong opioids should be avoided.
Moderate evidencePublished
Evidence hierarchy
Study participants
Adults with fibromyalgia syndrome meeting 1990 or 2010 American College of Rheumatology criteria.
Study Summary
This narrative review synthesizes interdisciplinary FMS management guidelines (Canada and Germany), Cochrane meta-analyses, and observational studies to appraise the current state of drug therapy for fibromyalgia syndrome (FMS). It concludes that there is no single gold-standard medication and that drug therapy is not mandatory. Amitriptyline, pregabalin, duloxetine, and milnacipran are positioned as first-line agents, but their average incremental benefit over placebo is small, only a minority of patients achieve substantial relief, and most eventually discontinue treatment because of inadequate efficacy or side effects. The authors emphasize tailoring drug choice to prominent comorbid symptoms, combining medication with self-management (exercise and psychological therapies), and discourage drug therapy as a sole strategy and the use of strong opioids.
Key Findings
| Finding | Detail | Impact |
|---|---|---|
| First-line FMS drugs offer only modest benefit and high discontinuation | Pregabalin, duloxetine, milnacipran, and amitriptyline are first-line agents, but the average incremental benefit over placebo is small; only a minority of patients experience substantial relief, and most discontinue because of lack of efficacy or tolerability problems. | High |
| About 30% pain relief in roughly half of patients; 50% relief in about a third | The review reports that the majority of medications can provide a 30% improvement in pain in about half of patients taking them, and a 50% improvement in pain in about a third of patients, but these gains do not translate into global improvement in well-being (SF-36 or Health Assessment Questionnaire). | High |
| Real-world centrally acting agents showed minimal change in pain, fatigue, and function | In an 11-year follow-up of about 3,123 US FMS patients (National Data Bank), use of pregabalin, gabapentin, duloxetine, or milnacipran rose from 10% to 39%, yet mean pain, fatigue, and disability did not change; among those started on these drugs, pain fell significantly by only 0.17 units (about 2.8%) with no significant improvement in fatigue or function. | High |
| Strong opioids are not recommended and lack supporting RCTs | No published RCTs examine strong opioids in FMS; despite this, about 11.3% of US and about 11% of German insured FMS patients received them. Both Canadian and German guidelines strongly discourage strong opioids, and strong opioids were ranked the number-one most harmful therapy in German consumer reports. | High |
| NSAIDs are not supported by evidence as monotherapy for FMS | Four RCTs (181 patients total) found no superiority over placebo after 1 to 8 weeks; the German guideline gave a negative recommendation, though some patients with comorbid osteoarthritis or inflammatory rheumatic disease report moderate benefit. | Medium |
| Drug choice should be tailored to comorbid symptoms | Amitriptyline or pregabalin for sleep disturbance, duloxetine for major depression, duloxetine or pregabalin for generalized anxiety disorder, and tramadol or duloxetine for comorbid osteoarthritis/rheumatic disease. | Medium |
| Tramadol and cyclobenzaprine are second-line options with limited evidence | Tramadol/acetaminophen was superior to placebo over 12 weeks in 313 patients; a meta-analysis of 5 RCTs (392 patients) found cyclobenzaprine-treated patients about three times more likely to report overall improvement after 4 to 24 weeks, and a 36-patient RCT showed low-dose cyclobenzaprine improved sleep at 8 weeks. | Medium |
| Placebo and nocebo responses are substantial in FMS drug trials | Estimates are that placebo and nocebo (dropout) effects account for up to 60% of measured drug efficacy and harms; deliberate use of positive expectation and a strong therapeutic relationship may bolster benefit. | Medium |
| Several promising drugs failed approval or remain experimental | Sodium oxybate showed efficacy in RCTs but was denied approval by FDA and EMA over safety/diversion concerns; serotonin receptor agonists (e.g., tropisetron) showed no significant superiority in meta-analysis; nabilone, growth hormone, quetiapine, and low-dose naltrexone showed limited or experimental-stage evidence. | Low |
Pregabalin, duloxetine, milnacipran, and amitriptyline are first-line agents, but the average incremental benefit over placebo is small; only a minority of patients experience substantial relief, and most discontinue because of lack of efficacy or tolerability problems.
The review reports that the majority of medications can provide a 30% improvement in pain in about half of patients taking them, and a 50% improvement in pain in about a third of patients, but these gains do not translate into global improvement in well-being (SF-36 or Health Assessment Questionnaire).
In an 11-year follow-up of about 3,123 US FMS patients (National Data Bank), use of pregabalin, gabapentin, duloxetine, or milnacipran rose from 10% to 39%, yet mean pain, fatigue, and disability did not change; among those started on these drugs, pain fell significantly by only 0.17 units (about 2.8%) with no significant improvement in fatigue or function.
No published RCTs examine strong opioids in FMS; despite this, about 11.3% of US and about 11% of German insured FMS patients received them. Both Canadian and German guidelines strongly discourage strong opioids, and strong opioids were ranked the number-one most harmful therapy in German consumer reports.
Four RCTs (181 patients total) found no superiority over placebo after 1 to 8 weeks; the German guideline gave a negative recommendation, though some patients with comorbid osteoarthritis or inflammatory rheumatic disease report moderate benefit.
Amitriptyline or pregabalin for sleep disturbance, duloxetine for major depression, duloxetine or pregabalin for generalized anxiety disorder, and tramadol or duloxetine for comorbid osteoarthritis/rheumatic disease.
Tramadol/acetaminophen was superior to placebo over 12 weeks in 313 patients; a meta-analysis of 5 RCTs (392 patients) found cyclobenzaprine-treated patients about three times more likely to report overall improvement after 4 to 24 weeks, and a 36-patient RCT showed low-dose cyclobenzaprine improved sleep at 8 weeks.
Estimates are that placebo and nocebo (dropout) effects account for up to 60% of measured drug efficacy and harms; deliberate use of positive expectation and a strong therapeutic relationship may bolster benefit.
Sodium oxybate showed efficacy in RCTs but was denied approval by FDA and EMA over safety/diversion concerns; serotonin receptor agonists (e.g., tropisetron) showed no significant superiority in meta-analysis; nabilone, growth hormone, quetiapine, and low-dose naltrexone showed limited or experimental-stage evidence.
Strengths
- Synthesizes multiple high-quality sources: two interdisciplinary consensus guidelines (Canada, Germany), Cochrane meta-analyses, and large observational datasets.
- Integrates real-world effectiveness data (cohorts, claims, consumer reports), not just RCT efficacy, giving a balanced view of clinical benefit.
- Provides concrete, practical prescribing guidance including starting and maximum doses and comorbidity-tailored drug selection.
- Authored by recognized experts who led the German and Canadian FMS guidelines and contributed to Cochrane reviews.
Limitations
- Narrative review rather than a systematic review or meta-analysis, so source selection and synthesis are not fully systematic.
- Underlying RCT evidence has limited external validity because trials uniformly excluded patients with inflammatory rheumatic disease and DSM-IV-defined psychological disorders.
- Evidence for several drugs (TCAs, SSRIs, tramadol, cyclobenzaprine, naltrexone, quetiapine) rests on small or older studies, limiting confidence.
- Multiple authors disclosed consulting and speaker honoraria from pharmaceutical companies, a potential conflict of interest.
- The two newer first-line agents were not approved by the EMA, reflecting unresolved questions about efficacy in some populations.
Key Takeaways for Patients
What This Means for You
- 01No single medication cures fibromyalgia, and drug therapy is not mandatory; for many people the best plan combines limited medication use with exercise and psychological self-management strategies.
- 02The main first-line drugs (amitriptyline, pregabalin, duloxetine, milnacipran) help only modestly: roughly half of users get about 30% pain relief and about a third get 50% relief, and many eventually stop because of side effects or insufficient benefit.
- 03Strong opioids are not recommended for fibromyalgia because there is no good evidence they work and they carry significant risks.
- 04Medication works best when matched to your most bothersome symptoms (such as poor sleep, depression, or anxiety) and started at a low dose with slow increases.
- 05A positive, trusting relationship with your clinician and realistic expectations can meaningfully influence how well treatment works and how many side effects you experience.
Read the Full Paper
Access the complete peer-reviewed study from Arthritis Research & Therapy
View Full Study